Glactone Pharma receives new funding from Vinnova

​In strong competition and after external examination, Glactone Pharma has been awarded a SEK 886,500 grant (approx. USD 106,000) from Vinnova (Sweden’s Innovation Agency) in the second phase of a program aimed at innovative startup companies. The funded project will be used to characterize Glactone Pharma’s lead STAT3 inhibitor, a potential new drug for the treatment of cancers.

Glactone Pharma granted patent for STAT3 inhibitors

Glactone Pharma has been granted a Swedish patent covering novel synthetic analogs of the STAT3 inhibitor GPA500 with improved druglike properties. Glactone Pharma is actively profiling small-molecule inhibitors of STAT3 as a potential new immunotherapy and for the treatment of drug resistant cancers.

Glactone Pharma receives funding from Vinnova

​In strong competition and after external examination, Glactone Pharma has been awarded a Vinnova (Sweden’s Innovation Agency) grant for innovative startup companies. The funded project will further investigate STAT3 as a target for cancer immunotherapy.

Share this page

Subscribe

Read more about our Protection of your personal data.